Adjuvant Radiation Therapy With Ifosfamide in Patients With Mixed Mesodermal Tumors of the Uterus
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The optimal sequence and /or modality for adjuvant therapy in the management of Mixed
Mesodermal Tumors (MMT) clearly remains to be established. The rationale for the protocol is
to "sandwich" pelvic radiation with chemotherapy to decrease distant metastasis.
The proposed study will sandwich radiation between the two most active chemotherapeutic
agents for MMT identified to date (ifosfamide/cisplatin). By doing so, we attempt to decrease
both local and distant recurrence, which may translate into an improved progression free
interval and possibly even extend survival.